U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07360301) titled 'Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study' on Jan. 13.
Brief Summary: This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
...